期刊
JOURNAL OF CONTROLLED RELEASE
卷 227, 期 -, 页码 71-81出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2016.02.032
关键词
Chitosan; Nanoparticles; siRNA; Galectin-1; Glioblastoma; Intranasal
资金
- IWT Flanders (SBO
- Strategisch Basis Onderzoek) [121206]
- BBTS (Belgian Brain Tumor Support)
- Olivia Hendrickx research fund
- Herman Memorial Research fund
- James E. Kearney Foundation
Galectin-1 (Gal-1) is a naturally occurring galactose-binding lectin, which is overexpressed in glioblastoma multiforme (GBM). Gal-1 is associated with tumor progression, and is a potent immune suppressor in the tumor micro-environment. To inhibit Gal-1 in GBM, an effective therapy is required that reaches the central nervous system tumor, with limited systemic effects. In this study, we report for the first time that concentrated chitosan nanoparticle suspensions can deliver small interfering RNA (siRNA) into the central nervous system tumor within hours after intranasal administration. These nanoparticles are able to complex siRNA targeting Gal-1 to a high percentage, and protect them from RNAse degradation. Moreover, a successful intracellular delivery of anti-Gal-1 siRNA resulted in a decreased expression of Gal-1 in both murine and human GBM cells. Sequence specific RNAinterference, resulted in more than 50% Gal-1 reduction in tumor bearing mice. This study indicates that the intranasal pathway is an underexplored transport route for delivering siRNA-based therapies targeting Gal-1 in the treatment of GBM. (C) 2016 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据